Brodalumab is a recombinant human IgG2 monoclonal antibody against human interleukin-17 receptor A monoclonal antibody. Brodalumab is produced in Chinese hamster ovary cells. Brodalumab is a glycoprotein (molecular weight: ca. 147,000) composed of 2 H-chains (γ2- chains) consisting of 442 amino acid residues each and 2 L-chains (κ-chains) consisting of 214 amino acid residues each.